Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study-Reference-Cited by-同舟云学术

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Published:2020-04 Issue:10231 Volume:395 Page:1208-1216
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Hofman Michael S,Lawrentschuk Nathan,Francis Roslyn J,Tang Colin,Vela Ian,Thomas Paul,Rutherford Natalie,Martin Jarad M,Frydenberg Mark,Shakher Ramdave,Wong Lih-Ming,Taubman Kim,Ting Lee Sze,Hsiao Edward,Roach Paul,Nottage Michelle,Kirkwood Ian,Hayne Dickon,Link Emma,Marusic Petra,Matera Anetta,Herschtal Alan,Iravani Amir,Hicks Rodney J,Williams Scott,Murphy Declan G

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy;Zumsteg;Eur Urol,2015

2. Predicting 15-year prostate cancer specific mortality after radical prostatectomy;Eggener;J Urol,2011

3. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology;Mohler;J Natl Compr Canc Netw,2019

4. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection;Briganti;Eur Urol,2012

Cited by 1270 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer;European Journal of Radiology;2024-11

2. Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study;European Urology Open Science;2024-10

3. Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics;Radiotherapy and Oncology;2024-10

4. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

5. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer;Clinical and Translational Oncology;2024-09-12